Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Aging Cell ; : e14211, 2024 May 28.
Article in English | MEDLINE | ID: mdl-38804500

ABSTRACT

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disorder affecting the central nervous system. Evidence suggests that age-related neurodegeneration contributes to disability progression during the chronic stages of MS. Aging is characterized by decreased regeneration potential and impaired myelin repair in the brain. It is hypothesized that accelerated cellular aging contributes to the functional decline associated with neurodegenerative diseases. We assessed the impact of aging on myelin content in the corpus callosum (CC) and compared aging with the long-term demyelination (LTD) consequents induced by 12 weeks of feeding with a cuprizone (CPZ) diet. Initially, evaluating myelin content in 2-, 6-, and 18-month-old mice revealed a reduction in myelin content, particularly at 18 months. Myelin thickness was decreased and the g-ratio increased in aged mice. Although a lower myelin content and higher g-ratio were observed in LTD model mice, compared to the normally aged mice, both aging and LTD exhibited relatively similar myelin ultrastructure. Our findings provide evidence that LTD exhibits the hallmarks of aging such as elevated expression of senescence-associated genes, mitochondrial dysfunction, and high level of oxidative stress as observed following normal aging. We also investigated the senescence-associated ß-galactosidase activity in O4+ late oligodendrocyte progenitor cells (OPCs). The senescent O4+/ß-galactosidase+ cells were elevated in the CPZ diet. Our data showed that the myelin degeneration in CC occurs throughout the lifespan, and LTD induced by CPZ accelerates the aging process which may explain the impairment of myelin repair in patients with progressive MS.

2.
Biochim Biophys Acta Proteins Proteom ; 1871(2): 140883, 2023 02 01.
Article in English | MEDLINE | ID: mdl-36455808

ABSTRACT

Multidrug resistance of bacteria and persistent infections related to biofilms, as well as the low availability of new antibacterial drugs, make it urgent to develop new antibiotics. Here, we evaluate the antibacterial and anti-biofilm properties of ticlopidine (TP), an anti-platelet aggregation drug, TP showed antibacterial activity against both gram-positive (MRSA) and gram-negative (E. coli, and P. aeruginosa) bacteria over a long treatment period. TP significantly reduced the survival of gram-negative bacteria in human blood though impact on gram-positives was more limited. TP may cause death in MRSA by inhibiting staphyloxanthin pigment synthesis, leading to oxidative stress, while scanning electron microscopy imaging indicate a loss of membrane integrity, damage, and consequent death due to lysis in gram-negative bacteria. TP showed good anti-biofilm activity against P. aeruginosa and MRSA, and a stronger biofilm degradation activity on P. aeruginosa compared to MRSA. Measuring fluorescence of the amyloid-reporter Thioflavin T (ThT) in biofilm implicated inhibition of amyloid formation as part of TP activity. This was confirmed by assays on the purified protein in P. aeruginosa, FapC, whose fibrillation kinetics was inhibited by TP. TP prolonged the lag phase of aggregation and reduced the subsequent growth rate and prolonging the lag phase to very long times provides ample opportunity to exert TP's antibacterial effect. We conclude that TP shows activity as an antibiotic against both gram-positive and gram-negative bacteria thanks to a broad range of activities, targeting bacterial metabolic processes, cellular structures and the biofilm matrix.


Subject(s)
Anti-Bacterial Agents , Escherichia coli , Humans , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Gram-Negative Bacteria/physiology , Gram-Positive Bacteria , Biofilms
3.
Clin Exp Pharmacol Physiol ; 47(9): 1575-1583, 2020 09.
Article in English | MEDLINE | ID: mdl-32367550

ABSTRACT

Drug-induced phospholipidosis (DIPL) is characterized by phospholipid storage in the lysosomes of affected tissues. Many severe effects and toxicities have been linked to DIPL. The aim of this study was to determine whether the endogenous opioid system is involved in chloroquine-induced phospholipidosis. The effect of naltrexone as an antagonist of opioid receptors in chloroquine-induced phospholipidosis in rat liver was investigated by morphological, biochemical, and molecular modelling studies. Transmission electron microscopy (TEM) showed that morphological characteristic changes of rat liver, including the number of lamellar bodies, grade of vacuolization and cell steatosis, were markedly attenuated in rats treated with naltrexone alone or in combination with chloroquine, in comparison with chloroquine-treated rats. The results of liquid chromatography mass spectrometry (LC/MS) showed that the concentrations of phenylacetylglycine (PAG) and hippuric acid (HA) were significantly decreased and increased, respectively, in target groups. Besides, the concentration ratio of PAG/HA was significantly decreased. Spectrophotometry resulted in a notable decrease in alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities in target groups. The results from the molecular docking and molecular dynamic simulation studies demonstrated clear chloroquine interaction with the active site cavity of the µ opioid receptor. These data suggest that administration of naltrexone alone, or in combination with chloroquine, notably attenuates the side effects of chloroquine-induced phospholipidosis, as well as demonstrating an increased probability of the endogenous opioid system involvement in chloroquine-induced phospholipidosis in rat liver.


Subject(s)
Chemical and Drug Induced Liver Injury/metabolism , Fatty Liver/metabolism , Liver/metabolism , Opioid Peptides/metabolism , Phospholipids/metabolism , Receptors, Opioid, mu/metabolism , Animals , Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/pathology , Chemical and Drug Induced Liver Injury/prevention & control , Chloroquine , Disease Models, Animal , Fatty Liver/chemically induced , Fatty Liver/pathology , Fatty Liver/prevention & control , Glycine/analogs & derivatives , Glycine/blood , Hippurates/blood , Liver/drug effects , Liver/ultrastructure , Male , Molecular Docking Simulation , Molecular Dynamics Simulation , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Rats , Signal Transduction
4.
Int J Biol Macromol ; 103: 709-720, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28545969

ABSTRACT

Increasing body of evidence suggests that polyphenols frequently interacting with amyloid aggregates and/or interfering with aggregate species to bind biomembranes may serve as a therapeutic approach for the treatment of amyloid-related diseases. Hence, in the present study, the possible effects of three naturally occurring polyphenols including Curcumin, Quercetin, and Resveratrol on mitochondrial membrane permeabilization induced by Hen Egg White Lysozyme (HEWL) oligomers were investigated. Our results indicated that pre-incubation of mitochondrial homogenate with polyphenols considerably inhibit membrane permeabilization in a concentration dependent manner. In parallel, HEWL oligomers, which were co-incubated with the polyphenols, showed less effectiveness on membrane permeabilization, suggesting that toxicity of oligomers was hindered. Using a range of techniques including fluorescence quenching, Nile red binding assay, zeta potential and size measurements, CD (far- and near-UV) spectroscopy, and molecular docking, we found that the polyphenols, structure-dependently, interact with and induce conformational changes in HEWL oligomers, thereby inhibit their toxicity. We proposed a mechanism by which selected polyphenols induce their protective effects through binding to mitochondria and interfering with HEWL oligomer-membrane interactions and/or by direct interaction with HEWL oligomers, induction of conformational changes, and generating far less toxic species. However, additional studies are needed to elucidate the detailed mechanisms involved.


Subject(s)
Mitochondrial Membranes/drug effects , Mitochondrial Membranes/metabolism , Muramidase/chemistry , Polyphenols/pharmacology , Protein Multimerization , Animals , Kinetics , Molecular Docking Simulation , Muramidase/metabolism , Permeability/drug effects , Polyphenols/metabolism , Protein Structure, Quaternary , Rats
5.
Biopolymers ; 102(6): 473-86, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25297917

ABSTRACT

The 25-35 fragment of the amyloid ß (Aß) peptide is a naturally occurring proteolytic by-product that retains the pathophysiology of its larger parent molecule, whose deposition has been shown to involve mitochondrial dysfunction. Hence, disruption of Aß(25-35) aggregates could afford an effective remedial strategy for Alzheimer's disease (AD). In the present study, the effect of a number of selected small-molecule natural products (polyphenols: resveratrol, quercetin, biochanin A, and indoles: indole-3-acetic acid, indole-3-carbinol (I3C)) on Aß(25-35) fibrillogenesis was explored under physiological conditions, and interaction of the resulting structures with rat brain mitochondria was investigated. Several techniques, including fluorescence, circular dichroism, and transmission electron microscopy were utilized to characterize the aggregation products, and possible mitochondrial membrane permeabilization was determined following release of marker enzymes. Results demonstrate the capacity of Aß(25-35) fibrils to damage mitochondria and suggest how small molecules may afford protection. While I3C appeared more effective in inhibiting the fibrillation process, all natural products behaved similarly in destabilizing preformed aggregates. It is concluded that elucidation of such protection may provide important insights into the development of preventive and therapeutic agents for AD.


Subject(s)
Amyloid beta-Peptides/metabolism , Biological Products/pharmacology , Mitochondria/metabolism , Peptide Fragments/metabolism , Small Molecule Libraries/pharmacology , Amyloid/metabolism , Animals , Biological Products/chemistry , Circular Dichroism , Male , Mitochondria/drug effects , Mitochondria/enzymology , Mitochondria/ultrastructure , Mitochondrial Membranes/drug effects , Mitochondrial Membranes/metabolism , Protein Binding/drug effects , Protein Structure, Secondary , Rats , Small Molecule Libraries/chemistry
6.
Brain Res ; 963(1-2): 93-100, 2003 Feb 14.
Article in English | MEDLINE | ID: mdl-12560114

ABSTRACT

Here, we examined chronic exposure to morphine to determine if this treatment shifted LTP mechanism in the CA1 field in vitro. Long-term potentiation (LTP) of population spikes induced by a 200 Hz theta pattern primed bursts (PBs) stimulation. Verapamil was used to isolate NMDA-dependent LTP. In control slices, a 200 Hz tetanus induced a compound potentiation, consisted of two pharmacologically separable components: nmdaLTP and vdccLTP. LTP in slices taken from morphine dependent rats was completely abolished by either APV or verapamil. These data suggest that morphine dependence in rats does not interfere with the induction and maintenance of hippocampal CA1 LTP. While in control rats both NMDA and voltage-dependent Ca(2+) channel (VDCC) antagonists must have been used concurrently to prevent the induction of LTP, in morphine-dependent rats, each of the antagonist could prevent the LTP induction suggesting a tighter coupling between these two calcium influx regulating processes.


Subject(s)
Hippocampus/physiopathology , Long-Term Potentiation/drug effects , Morphine Dependence/physiopathology , 2-Amino-5-phosphonovalerate/pharmacology , Animals , Behavior, Animal/drug effects , Calcium Channel Blockers/pharmacology , Cognition/drug effects , Electric Stimulation , Electrodes, Implanted , Excitatory Amino Acid Antagonists/pharmacology , Hippocampus/drug effects , In Vitro Techniques , Male , Memory/drug effects , Rats , Substance Withdrawal Syndrome/psychology , Synapses/drug effects , Verapamil/pharmacology
7.
Brain Res ; 965(1-2): 108-13, 2003 Mar 07.
Article in English | MEDLINE | ID: mdl-12591126

ABSTRACT

The effect of chronic morphine treatment on hippocampal CA1-long-term potentiation (LTP) was examined in vitro. The field excitatory postsynaptic potential (fEPSP) was recorded from stratum radiatum of area CA1 following stimulation of Schaffer collaterals in slices taken from control and morphine-dependent rats. To induce LTP, a 100-Hz primed burst stimulation (PBs) was used. Slices from rats exposed to chronic morphine showed no effect on baseline synaptic responses. Slices from control rats or rats exposed to chronic morphine maintained in ACSF with either morphine or naloxone also had no effect on baseline synaptic responses. Control slices perfused with medium containing either morphine or naloxone as well as both drugs exhibited hippocampal CA1 LTP. Similarly, slices from morphine-dependent rats maintained in ACSF with either naloxone or just morphine free ACSF also exhibited hippocampal CA1 LTP. However, slices from morphine-dependent rats maintained in ACSF with morphine significantly attenuated hippocampal CA1 LTP. These findings suggest that hippocampal CA1-LTP can still be achieved in slices from morphine-dependent rats exhibiting morphine withdrawal through mechanisms that may be inhibited by opiate exposure. Such studies can be helpful in understanding the neurophysiological substrate of memory deficits seen in opiate addicts.


Subject(s)
Hippocampus/drug effects , Long-Term Potentiation/drug effects , Morphine Dependence , Morphine/administration & dosage , Animals , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Hippocampus/physiology , In Vitro Techniques , Long-Term Potentiation/physiology , Male , Morphine Dependence/physiopathology , Rats
8.
Pharmacol Biochem Behav ; 72(1-2): 197-202, 2002 May.
Article in English | MEDLINE | ID: mdl-11900788

ABSTRACT

In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated. Morphine but not nicotine induced a dose-dependent catalepsy. The response of morphine was potentiated by nicotine. Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine. Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine. Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine. It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.


Subject(s)
Catalepsy/chemically induced , Morphine/pharmacology , Nicotine/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Synergism , Male , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...